Aziyo Biologics, Sientra Establish SimpliDerm Partnership

Aziyo Biologics Inc. and Sientra Inc. are teaming up to expand the distribution of Aziyo’s SimpliDerm product line. Under the formal agreement terms, Aziyo will grant Sientra certain non-exclusive rights in the United States to market, sell and distribute SimpliDerm for select use in reconstruction surgery.
 
“At Aziyo, our mission is to improve compatibility between medical devices and the patients they serve. With this partnership, we significantly expand women’s access to biologic solutions necessary for successful reconstruction procedures,” Aziyo Biologics President/CEO Randy Mills, Ph.D., said. “We are excited to partner with Sientra, a commercial company that brings a highly-specialized commercial team with reach and relationships to help drive growth of the SimpliDerm portfolio in reconstructive surgery. This agreement is intended to help drive meaningful revenue growth and support our strategy of quickly and profitably expanding the reach of our proprietary biologics platforms.”
 
SimpliDerm is a pre-hydrated human acellular dermal matrix (hADM) that uses a proprietary process to preserve key growth factors of native dermis that support faster integration and more rapid revascularization while demonstrating a lower risk of inflammatory response. Due to this unique process, SimpliDerm has been able to provide a pliable, conforming matrix in a ready-to-use format and achieve a sterility assurance level (SAL) of 10-6.
 
“At Sientra, we believe that putting the best products in the hands of the most qualified surgeons leads to the most optimal results. The partnership with Aziyo allows our customer to access the SimpliDerm portfolio to provide the industry’s most compelling reconstruction portfolio,” Sientra President/CEO Ron Menezes said. “The addition of SimpliDerm to our portfolio fits perfectly with our strategy of being the leader in reconstruction, while enhancing our path to profitability.”
 
SimpliDerm is to be used for the repair or replacement of damaged or insufficient integumental tissue or for other homologous uses of human integument.
 
Aziyo develops and commercializes biologic products to improve compatibility between medical devices and the patients who need them. 
 
Headquartered in Irvine, Calif., Sientra is a medical aesthetics company exclusively focused on plastic surgery. The company has developed a portfolio of products with technologically differentiated characteristics: including its Sientra round and shaped breast implants, the first fifth generation breast implants approved by the U.S. Food and Drug Administration for sale in the United States; Allox2 breast tissue expander with patented dual-port and integral drain technology; the Viality with AuraClens fat transfer system; and BIOCORNEUM, the top-performing, preferred and recommended scar gel of plastic surgeons.* 
 
* Data on file.